Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Mark Hopman sold 775 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $16.22, for a total transaction of $12,570.50. Following the transaction, the insider owned 54,143 shares of the company’s stock, valued at approximately $878,199.46. The trade was a 1.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Mark Hopman also recently made the following trade(s):
- On Monday, October 26th, Mark Hopman sold 821 shares of Beta Bionics stock. The shares were sold at an average price of $20.00, for a total value of $16,420.00.
- On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The stock was sold at an average price of $17.35, for a total value of $13,446.25.
- On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total value of $7,015.20.
- On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The stock was sold at an average price of $20.13, for a total value of $619,581.27.
- On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total value of $680,620.20.
- On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $101,798.97.
Beta Bionics Stock Down 2.6%
Shares of Beta Bionics stock opened at $14.33 on Thursday. Beta Bionics, Inc. has a 52 week low of $8.80 and a 52 week high of $32.71. The firm’s 50 day moving average is $18.23 and its two-hundred day moving average is $14.87. The firm has a market capitalization of $779.08 million, a P/E ratio of -7.79 and a beta of 3.44.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. The firm had revenue of $35.51 million for the quarter. As a group, research analysts expect that Beta Bionics, Inc. will post -2.04 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of BBNX. Legal & General Group Plc purchased a new stake in shares of Beta Bionics in the second quarter valued at about $62,000. The Manufacturers Life Insurance Company purchased a new position in shares of Beta Bionics during the second quarter worth about $172,000. 49 Wealth Management LLC acquired a new position in Beta Bionics in the 3rd quarter valued at about $260,000. Ieq Capital LLC acquired a new position in Beta Bionics in the 2nd quarter valued at about $229,000. Finally, Quantbot Technologies LP acquired a new position in shares of Beta Bionics in the second quarter valued at approximately $264,000.
Wall Street Analyst Weigh In
A number of analysts have recently commented on BBNX shares. Barclays began coverage on Beta Bionics in a research report on Tuesday, October 6th. They set an “overweight” rating and a $30.00 target price on the stock. Bank of America raised their price target on Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. Jefferies Financial Group assumed coverage on Beta Bionics in a research report on Monday, October 12th. They set a “buy” rating and a $30.00 price target on the stock. Wall Street Zen cut Beta Bionics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.69.
Get Our Latest Research Report on Beta Bionics
Beta Bionics Company Profile
Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.
Further Reading
- Five stocks we like better than Beta Bionics
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
